Disulfide-rich macrocyclic peptides as templates in drug design

European Journal of Medicinal Chemistry

Volumn 77, Issue , 2014, Pages 248-257

  Northfield, Susan E ^a   Wang, Conan K ^a   Schroeder, Christina I ^a   Durek, Thomas ^a   Kan, Meng Wei ^a   Swedberg, Joakim E ^a   Craik, David J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cyclic peptide; Cyclotide; Disulfide bonds; Grafting

Indexed keywords

BETA DEFENSIN; BIOLOGICAL PRODUCT; BOCEPREVIR; CARFILZOMIB; CONOTOXIN; CYCLOPEPTIDE; CYCLOSPORIN A; CYCLOTIDE; DISULFIDE; EPITOPE; HEPCIDIN; ICATIBANT; KYPOLIS; LINACLOTIDE; LUCINACTANT; MOLECULAR SCAFFOLD; OMEGA CONOTOXIN; PASIREOTIDE; PEGINESATIDE; PEPTIDOMIMETIC AGENT; TEDUGLUTIDE; TELAPREVIR; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; MACROCYCLIC COMPOUND;

BIOLOGICAL ACTIVITY; DISULFIDE BOND; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG METABOLISM; DRUG PENETRATION; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG TARGETING; HUMAN; IMMUNOGENICITY; MOLECULAR WEIGHT; NONHUMAN; PROTEIN ENGINEERING; PROTEIN TARGETING; REVIEW; CHEMISTRY; CONFORMATION; SYNTHESIS;

DISULFIDES; DRUG DESIGN; MACROCYCLIC COMPOUNDS; MOLECULAR CONFORMATION; PEPTIDES, CYCLIC;

EID: 84896512272     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.03.011     Document Type: Review

References (128)

1. C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Advanced Drug Delivery Reviews 23 (1997) 3-25. (Pubitemid 27046991)
2. M. Góngora-Benítez, J. Tulla-Puche, F. Albericio, Multifaceted roles of disulfide bonds. Peptides as therapeutics, Chemical Reviews 114 (2014) 901-926.
3. P. Vlieghe, V. Lisowski, J. Martinez, M. Khrestchatisky, Synthetic therapeutic peptides: science and market, Drug Discovery Today 15 (2010) 40-56.
4. D.J. Craik, D.P. Fairlie, S. Liras, D. Price, The future of peptide-based drugs, Chemical Biology & Drug Design 81 (2013) 136-147.
5. E. Montanya, A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes, Expert Opinion on Pharmacotherapy 13 (2012) 1451-1467.
6. New Drugs at FDA: CDER's New Molecular Entities and New Therapeutic Biological Products of 2013, http://www.fda.gov/, (accessed on 18.12.13).
7. A. Mullard, 2011 FDA drug approvals, Natural Reviews Drug Discovery 11 (2012) 91-94.
8. A. Mullard, 2012 FDA drug approvals, Natural Reviews Drug Discovery 12 (2013) 87-90.
9. M.A. Yildirim, K.-I. Goh, M.E. Cusick, A.-L. Barabasi, M. Vidal, Drug-target network, Nature Biotechnology 25 (2007) 1119-1126. (Pubitemid 47538114)
10. L.N. Makley, J.E. Gestwicki, Expanding the number of 'druggable' targets: non-enzymes and proteineprotein interactions, Chemical Biology & Drug Design 81 (2013) 22-32.
11. M.C. Smith, J.E. Gestwicki, Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity, Expert Reviews in Molecular Medicine 14 (2012) e16-e35.
12. N.C. Wrighton, F.X. Farrell, R. Chang, A.K. Kashyap, F.P. Barbone, L.S. Mulcahy, D.L. Johnson, R.W. Barrett, L.K. Jolliffe, W.J. Dower, Small peptides as potent mimetics of the protein hormone erythropoietin, Science 273 (1996) 458-463. (Pubitemid 26286441)
13. N.C. Wrighton, P. Balasubramanian, F.P. Barbone, A.K. Kashyap, F.X. Farrell, L.K. Jolliffe, R.W. Barrett, W.J. Dower, Increased potency of an erythropoietin peptide mimetic through covalent dimerization, Nature Biotechnology 15 (1997) 1261-1265. (Pubitemid 27465136)
14. K.W. Woodburn, K.-L. Fong, S.D. Wilson, S. Sloneker, P. Strzemienski, E. Solon, Y. Moriya, Y. Tagawa, Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration, Drug Metabolism and Disposition 41 (2013) 774-784.
15. Omontys (Peginesatide) Injection by Affymax and Takeda: Recall of All Lots-Serious Hypersensitivity Reactions, Dec. 18, 2013. http://www.fda.gov/.
16. A. Fahr, Cyclosporin clinical pharmacokinetics, Clinical Pharmacokinetics 24 (1993) 472-495. (Pubitemid 23160616)
17. J. Clardy, C. Walsh, Lessons from natural molecules, Nature 432 (2004) 829-837. (Pubitemid 40037138)
18. I. Paterson, E.A. Anderson, The renaissance of natural products as drug candidates, Science 310 (2005) 451-453. (Pubitemid 41507948)
19. I. Vetter, J. Davis, L. Rash, R. Anangi, M. Mobli, P. Alewood, R. Lewis, G. King, Venomics: a new paradigm for natural products-based drug discovery, Amino Acids 40 (2011) 15-28.
20. ™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs, Future Medicinal Chemistry 5 (2013) 291-300.
21. P.R. Weiglmeier, P. Rösch, H. Berkner, Cure and curse: E. coli heat-stable enterotoxin and its receptor guanylyl cyclase C, Toxins 2 (2010) 2213-2229.
22. I. Azimi, J.W.H. Wong, P.J. Hogg, Control of mature protein function by allosteric disulfide bonds, Antioxidants & Redox Signaling 14 (2010) 113-126.
23. V.J. Hruby, Designing peptide receptor agonists and antagonists, Nature Reviews. Drug Discovery 1 (2002) 847-858. (Pubitemid 37361580)
24. T.N. Vinther, M. Norrman, U. Ribel, K. Huus, M. Schlein, D.B. Steensgaard, T.Å. Pedersen, I. Pettersson, S. Ludvigsen, T. Kjeldsen, K.J. Jensen, F. Hubálek, Insulin analog with additional disulfide bond has increased stability and preserved activity, Protein Science 22 (2013) 296-305.
25. H. Andersson, H. Demaegdt, G. Vauquelin, G. Lindeberg, A. Karlen, M. Hallberg, M.t. Erdelyi, A. Hallberg, Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP), Journal of Medicinal Chemistry 53 (2010) 8059-8071.
26. G. Saito, J.A. Swanson, K.-D. Lee, Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities, Advanced Drug Delivery Reviews 55 (2003) 199-215. (Pubitemid 36135916)
27. G. Hussack, T. Hirama, W. Ding, R. MacKenzie, J. Tanha, Engineered single-domain antibodies with high protease resistance and thermal stability, PLoS ONE 6 (2011) e28218.
28. N. Germain, J.S. Minnion, T. Tan, J. Shillito, C. Gibbard, M. Ghatei, S. Bloom, Analogs of pancreatic polypeptide and peptide YY with a locked PP-fold structure are biologically active, Peptides 39 (2013) 6-10.
29. M. Jesus Perez de Vega, M. Martin-Martinez, R. Gonzalez-Muniz, Modulation of protein-protein interactions by stabilizing/mimicking protein secondary structure elements, Current Topics in Medicinal Chemistry 7 (2007) 33-62. (Pubitemid 46062396)
30. D.J. Craik, Chemistry. Seamless proteins tie up their loose ends, Science 311 (2006) 1563-1564.
31. A.C. Conibear, D.J. Craik, Chemical synthesis of naturally-occurring cyclic mini-proteins from plants and animals, Israel Journal of Chemistry 51 (2011) 908-916.
32. L. Thorstholm, D.J. Craik, Discovery and applications of naturally occurring cyclic peptides, Drug Discovery Today: Technologies 9 (2012) e13-e21.
33. D.J. Craik, N.M. Allewell, Thematic minireview series on circular proteins, Journal of Biological Chemistry 287 (2012) 26999-27000.
34. D.J. Craik, Protein folding: turbo-charged crosslinking, Nature Chemistry 4 (2012) 600-602.
35. M. Reinwarth, B. Glotzbach, M. Tomaszowski, S. Fabritz, O. Avrutina, H. Kolmar, Oxidative folding of peptides with cystine-knot architectures: kinetic studies and optimization of folding conditions, Chembiochem 14 (2013) 137-146.
36. T.L. Aboye, J.A. Camarero, Biological synthesis of circular polypeptides, Journal of Biological Chemistry 287 (2012) 27026-27032.
37. S. Fung, V.J. Hruby, Design of cyclic and other templates for potent and selective peptide α-MSH analogues, Current Opinion in Chemical Biology 9 (2005) 352-358. (Pubitemid 41019680)
38. M. Katsara, T. Tselios, S. Deraos, G. Deraos, M.-T. Matsoukas, E. Lazoura, J. Matsoukas, V. Apostolopoulos, Round and round we go: cyclic peptides in disease, Current Medicinal Chemistry 13 (2006) 2221-2232. (Pubitemid 44184648)
39. S. Luckett, R.S. Garcia, J.J. Barker, A.V. Konarev, P.R. Shewry, A.R. Clarke, R.L. Brady, High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds, Journal of Molecular Biology 290 (1999) 525-533. (Pubitemid 29324836)
40. 1H NMR of the novel cyclic trypsin inhibitor SFTI-1 from sun flower seeds and an acyclic permutant, Journal of Molecular Biology 311 (2001) 579-591.
41. M.L.J. Korsinczky, H.J. Schirra, D.J. Craik, Sunflower trypsin inhibitor-1, Current Protein and Peptide Science 5 (2004) 351-364. (Pubitemid 39200165)
42. R.-F. Qi, Z.-W. Song, C.-W. Chi, Structural features and molecular evolution of bowman-birk protease inhibitors and their potential application, Acta Biochimica et Biophysica Sinica 37 (2005) 283-292. (Pubitemid 41169475)
43. A. Lesner, A. Legowska, M. Wysocka, K. Rolka, Sunflower trypsin inhibitor 1 as a molecular scaffold for drug discovery, Current Pharmaceutical Design 17 (2011) 4308-4317.
44. P. Li, S. Jiang, S.-L. Lee, C.Y. Lin, M.D. Johnson, R.B. Dickson, C.J. Michejda, P.P. Roller, Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1, Journal of Medicinal Chemistry 50 (2007) 5976-5983.
45. P. Quimbar, U. Malik, C.P. Sommerhoff, Q. Kaas, L.Y. Chan, Y.-H. Huang, M. Grundhuber, K. Dunse, D.J. Craik, M.A. Anderson, N.L. Daly, High-affinity cyclic peptide matriptase inhibitors, Journal of Biological Chemistry 288 (2013) 13885-13896.
46. E. Zabłotna, K. Kaźmierczak, A. Jaśkiewicz, M. Stawikowski, G. Kupryszewski, K. Rolka, Chemical synthesis and kinetic study of the smallest naturally occurring trypsin inhibitor SFTI-1 isolated from sunflower seeds and its analogues, Biochemical and Biophysical Research Communications 292 (2002) 855-859.
47. M.L.J. Korsinczky, R.J. Clark, D.J. Craik, Disulfide bond mutagenesis and the structure and function of the head-to-tail macrocyclic trypsin inhibitor SFTI-1, Biochemistry 44 (2005) 1145-1153. (Pubitemid 40208994)
48. M.L. Colgrave, M.J.L. Korsinczky, R.J. Clark, F. Foley, D.J. Craik, Sunflower trypsin inhibitor-1, proteolytic studies on a trypsin inhibitor peptide and its analogs, Peptide Science 94 (2010) 665-672.
49. R.I. Lehrer, A.M. Cole, M.E. Selsted, θ-Defensins: cyclic peptides with endless potential, Journal of Biological Chemistry 287 (2012) 27014-27019.
50. T. Ganz, Defensins: antimicrobial peptides of innate immunity, Nature Reviews. Immunology 3 (2003) 710-720. (Pubitemid 41070812)
51. Y.-Q. Tang, J. Yuan, G. Ösapay, K. Ösapay, D. Tran, C.J. Miller, A.J. Ouellette, M.E. Selsted, A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated α-defensins, Science 286 (1999) 498-502.
52. A.E. Garcia, G. Ösapay, P.A. Tran, J. Yuan, M.E. Selsted, Isolation, synthesis, and antimicrobial activities of naturally occurring θ-defensin isoforms from baboon leukocytes, Infection and Immunity 76 (2008) 5883-5891.
53. A.C. Conibear, K.J. Rosengren, P.J. Harvey, D.J. Craik, Structural characterization of the cyclic cystine ladder motif of θ-defensins, Biochemistry 51 (2012) 9718-9726.
54. D. Tran, P. Tran, K. Roberts, G. Ösapay, J. Schaal, A. Ouellette, M.E. Selsted, Microbicidal properties and cytocidal selectivity of rhesus macaque theta defensins, Antimicrobial Agents and Chemotherapy 52 (2008) 944-953. (Pubitemid 351358374)
55. P. Tongaonkar, P. Tran, K. Roberts, J. Schaal, G. Ösapay, D. Tran, A.J. Ouellette, M.E. Selsted, Rhesus macaque θ-defensin isoforms: expression, antimicrobial activities, and demonstration of a prominent role in neutrophil granule microbicidal activities, Journal of Leukocyte Biology 89 (2011) 283-290.
56. E. Leikina, H. Delanoe-Ayari, K. Melikov, M.-S. Cho, A. Chen, A.J. Waring, W. Wang, Y. Xie, J.A. Loo, R.I. Lehrer, L.V. Chernomordik, Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins, Nature Immunology 6 (2005) 995-1001. (Pubitemid 41486184)
57. A.M. Cole, T. Hong, L.M. Boo, T. Nguyen, C. Zhao, G. Bristol, J.A. Zack, A.J. Waring, O.O. Yang, R.I. Lehrer, Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1, Proceedings of the National Academy of Sciences 99 (2002) 1813-1818. (Pubitemid 34168972)
58. W. Wang, C. Mulakala, S.C. Ward, G. Jung, H. Luong, D. Pham, A.J. Waring, Y. Kaznessis, W. Lu, K.A. Bradley, R.I. Lehrer, Retrocyclins kill bacilli and germinating spores of bacillus anthracis and inactivate anthrax lethal toxin, Journal of Biological Chemistry 281 (2006) 32755-32764. (Pubitemid 46036831)
59. J.B. Schaal, D. Tran, P. Tran, G. Ösapay, K. Trinh, K.D. Roberts, K.M. Brasky, P. Tongaonkar, A.J. Ouellette, M.E. Selsted, Rhesus macaque theta defensins suppress inflammatory cytokines and enhance survival in mouse models of bacteremic sepsis, PLoS ONE 7 (2012) e51337.
60. W.T. Penberthy, S. Chari, A. Cole, A. Cole, Retrocyclins and their activity against HIV-1, Cellular and Molecular Life Sciences 68 (2011) 2231-2242.
61. A.C. Conibear, K.J. Rosengren, N.L. Daly, S.T. Henriques, D.J. Craik, The cyclic cystine ladder in θ-defensins is important for structure and stability, but not antibacterial activity, Journal of Biological Chemistry 288 (2013) 10830-10840.
62. D.J. Craik, N.L. Daly, T. Bond, C. Waine, Plant cyclotides: a unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif, Journal of Molecular Biology 294 (1999) 1327-1336. (Pubitemid 30008803)
63. J.P. Mulvenna, C. Wang, D.J. Craik, CyBase: a database of cyclic protein sequence and structure, Nucleic Acids Research 34 (2006) D192-D194.
64. U. Göransson, R. Burman, S. Gunasekera, A.A. Strömstedt, K.J. Rosengren, Circular proteins from plants and fungi, Journal of Biological Chemistry 287 (2012) 27001-27006.
65. A.G. Poth, L.Y. Chan, D.J. Craik, Cyclotides as grafting frameworks for protein engineering and drug design applications, Peptide Science 100 (2013) 480-491.
66. C. Jennings, J. West, C. Waine, D. Craik, M. Anderson, Biosynthesis and insecticidal properties of plant cyclotides: the cyclic knotted proteins from Oldenlandia af finis, Proceedings of the National Academy of Sciences 98 (2001) 10614-10619. (Pubitemid 32878669)
67. L. Gran, F. Sandberg, K. Sletten, Oldenlandia affinis (R&S) DC: a plant containing uteroactive peptides used in African traditional medicine, Journal of Ethnopharmacology 70 (2000) 197-203. (Pubitemid 30317360)
68. K.R. Gustafson, T.C. McKee, H.R. Bokesch, Anti-HIV cyclotides, Current Protein and Peptide Science 5 (2004) 331-340. (Pubitemid 39200163)
69. J.P. Tam, Y.-A. Lu, J.-L. Yang, K.-W. Chiu, An unusual structural motif of antimicrobial peptides containing end-to-end macrocycle and cystine-knot disulfides, Proceedings of the National Academy of Sciences 96 (1999) 8913-8918. (Pubitemid 29374682)
70. E. Svangard, U. Goransson, Z. Hocaoglu, J. Gullbo, R. Larsson, P. Claeson, L. Bohlin, Cytotoxic cyclotides from viola tricolor, Journal of Natural Products 67 (2004) 144-147. (Pubitemid 38282899)
71. C. Gründemann, K. Thell, K. Lengen, M. Garcia-Käufer, Y.-H. Huang, R. Huber, D.J. Craik, G. Schabbauer, C.W. Gruber, Cyclotides suppress human T-lymphocyte proliferation by an interleukin 2-dependent mechanism, PLoS ONE 8 (2013) e68016.
72. M.L. Colgrave, D.J. Craik, Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot, Biochemistry 43 (2004) 5965-5975. (Pubitemid 38669464)
73. R.J. Clark, J. Jensen, S.T. Nevin, B.P. Callaghan, D.J. Adams, D.J. Craik, The engineering of an orally active conotoxin for the treatment of neuropathic pain, Angewandte Chemie International Edition 49 (2010) 6545-6548.
74. E.S. Lovelace, C.J. Armishaw, M.L. Colgrave, M.E. Wahlstrom, P.F. Alewood, N.L. Daly, D.J. Craik, Cyclic MrIA: a stable and potent cyclic conotoxin with a novel topological fold that targets the norepinephrine transporter, Journal of Medicinal Chemistry 49 (2006) 6561-6568. (Pubitemid 44657450)
75. M. Akcan, M.R. Stroud, S.J. Hansen, R.J. Clark, N.L. Daly, D.J. Craik, J.M. Olson, Chemical re-engineering of chlorotoxin improves bioconjugation properties for tumor imaging and targeted therapy, Journal of Medicinal Chemistry 54 (2011) 782-787.
76. R.J. Clark, G.C. Preza, C.C. Tan, J.W.A. van Dijk, E. Fung, E. Nemeth, T. Ganz, D.J. Craik, Design, synthesis, and characterization of cyclic analogues of the iron regulatory peptide hormone hepcidin, Peptide Science 100 (2013) 519-526.
77. H. Terlau, B.M. Olivera, Conus venoms: a rich source of novel ion channel-targeted peptides, Physiological Reviews 84 (2004) 41-68. (Pubitemid 38049875)
78. C.I. Schroeder, D.J. Craik, Therapeutic potential of conopeptides, Future Medicinal Chemistry 4 (2012) 1243-1255.
79. Q. Kaas, J.-C. Westermann, R. Halai, C.K.L. Wang, D.J. Craik, ConoServer, a database for conopeptide sequences and structures, Bioinformatics 24 (2008) 445-446. (Pubitemid 351189028)
80. Q. Kaas, J.-C. Westermann, D.J. Craik, Conopeptide characterization and classifications: an analysis using ConoServer, Toxicon 55 (2010) 1491-1509.
81. R.J. Clark, D.J. Craik, Chapter three - engineering cyclic peptide toxins, in: K.D. Wittrup, L.V. Gregory (Eds.), Methods in Enzymology, Academic Press, 2012, pp. 57-74.
82. R.J. Clark, H. Fischer, L. Dempster, N.L. Daly, K.J. Rosengren, S.T. Nevin, F.A. Meunier, D.J. Adams, D.J. Craik, Engineering stable peptide toxins by means of backbone cyclization: Stabilization of the α-conotoxin MII, Proceedings of the National Academy of Sciences of the United States of America 102 (2005) 13767-13772. (Pubitemid 41377653)
83. R. Halai, B. Callaghan, N.L. Daly, R.J. Clark, D.J. Adams, D.J. Craik, Effects of cyclization on stability, structure, and activity of α-conotoxin RgIA at the α9α10 nicotinic acetylcholine receptor and GABAB receptor, Journal of Medicinal Chemistry 54 (2011) 6984-6992.
84. E.S. Lovelace, G.S.,A.C.,R.J. Clark, S.T. Nevin, G.A.A.,D.J. Adams, D. Craik, N.L. Daly, Stabilization of α-conotoxin AuIB: influences of disulfide connectivity and backbone cyclization, Antioxidants & Redox Signaling 14 (2011) 87-95.
85. C.J. Armishaw, J.L. Dutton, D.J. Craik, P.F. Alewood, Establishing regiocontrol of disulfide bond isomers of α-conotoxin ImI via the synthesis of N-to-C cyclic analogs, Peptide Science 94 (2010) 307-313.
86. I.A. Sharpe, J. Gehrmann, M.L. Loughnan, L. Thomas, D.A. Adams, A. Atkins, E. Palant, D.J. Craik, D.J. Adams, P.F. Alewood, R.J. Lewis, Two new classes of conopeptides inhibit the α1-adrenoceptor and noradrenaline transporter, Nature Neuroscience 4 (2001) 902-907. (Pubitemid 32801593)
87. R.J. Lewis, Discovery and development of the χ-conopeptide class of analgesic peptides, Toxicon 59 (2012) 524-528.
88. B. Olivera, W. Gray, R. Zeikus, J. McIntosh, J. Varga, J. Rivier, V. de Santos, L. Cruz, Peptide neurotoxins from fish-hunting cone snails, Science 230 (1985) 1338-1343. (Pubitemid 16105162)
89. S.S. Bowersox, R. Luther, Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus, Toxicon 36 (1998) 1651-1658. (Pubitemid 28511080)
90. C.P. Scott, E. Abel-Santos, M. Wall, D.C. Wahnon, S.J. Benkovic, Production of cyclic peptides and proteins in vivo, Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 13638-13643.
91. R.J. Lewis, S. Dutertre, I. Vetter, M.J. Christie, Conus venom peptide pharmacology, Pharmacological Reviews 64 (2012) 259-298.
92. X. Hemu, M. Taichi, Y. Qiu, D.-X. Liu, J.P. Tam, Biomimetic synthesis of cyclic peptides using novel thioester surrogates, Peptide Science 100 (2013) 492-501.
93. J.A. DeBin, J.E. Maggio, G.R. Strichartz, Purification an characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion, American Journal of Physiology 264 (1993) C2361-C2369.
94. S.A. Lyons, J. O'Neal, H. Sontheimer, Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin, Glia 39 (2002) 162-173. (Pubitemid 34817056)
95. L. Soroceanu, Y. Gillespie, M.B. Khazaeli, H. Sontheimer, Use of chlorotoxin for targeting of primary brain tumors, Cancer Research 58 (1998) 4871-4879. (Pubitemid 28503684)
96. J. Deshane, C.C. Garner, H. Sontheimer, Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2, Journal of Biological Chemistry 278 (2003) 4135-4144. (Pubitemid 36801150)
97. K. Kesavan, J. Ratliff, E.W. Johnson, W. Dahlberg, J.M. Asara, P. Misra, J.V. Frangioni, D.B. Jacoby, Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects, Journal of Biological Chemistry 285 (2010) 4366-4374.
98. M. Veiseh, P. Gabikian, S.-B. Bahrami, O. Veiseh, M. Zhang, R.C. Hackman, A.C. Ravanpay, M.R. Stroud, Y. Kusuma, S.J. Hansen, D. Kwok, N.M. Munoz, R.W. Sze, W.M. Grady, N.M. Greenberg, R.G. Ellenbogen, J.M. Olson, Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci, Cancer Research 67 (2007) 6882-6888. (Pubitemid 47105535)
99. M. Wiranowska, L. Colina, J. Johnson, Clathrin-mediated entry and cellular localization of chlorotoxin in human glioma, Cancer Cell International 11 (2011) 27.
100. P.M. Costa, A.L. Cardoso, L.S. Mendonca, A. Serani, C. Custodia, M. Conceicao, S. Simoes, J.N. Moreira, L. Pereira de Almeida, M.C. Pedroso de Lima, Tumor-targeted chlorotoxin-coupled nanoparticles for nucleic acid delivery to glioblastoma cells: a promising system for glioblastoma treatment, Molecular Therapy - Nucleic Acids 2 (2013) e100.
101. E. Nemeth, M.S. Tuttle, J. Powelson, M.B. Vaughn, A. Donovan, D.M. Ward, T. Ganz, J. Kaplan, Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization, Science 306 (2004) 2090-2093. (Pubitemid 40007660)
102. J.B. Jordan, L. Poppe, M. Haniu, T. Arvedson, R. Syed, V. Li, H. Kohno, H. Kim, P.D. Schnier, T.S. Harvey, L.P. Miranda, J. Cheetham, B.J. Sasu, Hepcidin revisited, disulfide connectivity, dynamics, and structure, Journal of Biological Chemistry 284 (2009) 24155-24167.
103. E. Nemeth, G.C. Preza, C.-L. Jung, J. Kaplan, A.J. Waring, T. Ganz, The N-terminus of hepcidin is essential for its interaction with ferroportin: structurefunction study, Blood 107 (2006) 328-333. (Pubitemid 43053559)
104. L.Y. Chan, S. Gunasekera, S.T. Henriques, N.F. Worth, S.J. Le, R.J. Clark, J.H. Campbell, D.J. Craik, N.L. Daly, Engineering pro-angiogenic peptides using stable, disulfide-rich cyclic scaffolds, Blood 118 (2011) 6709-6717.
105. A.C. Conibear, A. Bochen, K.J. Rosengren, P. Stupar, C.K. Wang, H. Kessler, D.J. Craik, The cyclic cystine ladder of theta-defensins as a stable, bifunctional scaffold: a proof-of-concept study using integrin-binding RGD motif, Chembiochem 15 (2014) 451-459.
106. Y. Ji, S. Majumder, M. Millard, R. Borra, T. Bi, A.Y. Elnagar, N. Neamati, A. Shekhtman, J.A. Camarero, In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide, Journal of the American Chemical Society 135 (2013) 11623-11633.
107. J.E. Swedberg, L.V. Nigon, J.C. Reid, S.J. de Veer, C.M. Walpole, C.R. Stephens, T.P. Walsh, T.K. Takayama, J.D. Hooper, J.A. Clements, A.M. Buckle, J.M. Harris, Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4, Chemistry & Biology 16 (2009) 633-643.
108. C.K. Wang, C.W. Gruber, M. Cemazar, C. Siatskas, P. Tagore, N. Payne, G. Sun, S. Wang, C.C. Bernard, D.J. Craik, Molecular grafting onto a stable framework yields novel cyclic peptides for the treatment of multiple sclerosis, ACS Chemical Biology 9 (2014) 156-163.
109. J.E. Swedberg, S.J. de Veer, K.C. Sit, C.F. Reboul, A.M. Buckle, J.M. Harris, Mastering the canonical loop of serine protease inhibitors: enhancing potency by optimising the internal hydrogen bond network, PLoS ONE 6 (2011) e19302.
110. D.J. Craik, J.E. Swedberg, J.S. Mylne, M. Cemazar, Cyclotides as a basis for drug design, Expert Opinion on Drug Discovery 7 (2012) 179-194.
111. P. Carmeliet, Angiogenesis in life, disease and medicine, Nature 438 (2005) 932-936. (Pubitemid 43093958)
112. M. Simons, J.A. Ware, Therapeutic angiogenesis in cardiovascular disease, Nature Reviews. Drug Discovery 2 (2003) 863-872.
113. T. Sweeney, M. Kibbey, M. Zain, R. Fridman, H. Kleinman, Basement membrane and the SIKVAV laminin-derived peptide promote tumor growth and metastases, Cancer and Metastasis Reviews 10 (1991) 245-254.
114. Y. Hamada, K. Nokihara, M. Okazaki, W. Fujitani, T. Matsumoto, M. Matsuo, Y. Umakoshi, J. Takahashi, N. Matsuura, Angiogenic activity of osteopontin-derived peptide SVVYGLR, Biochemical and Biophysical Research Communications 310 (2003) 153-157. (Pubitemid 37168007)
115. L.D. D'Andrea, G. Iaccarino, R. Fattorusso, D. Sorriento, C. Carannante, D. Capasso, B. Trimarco, C. Pedone, Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide, Proceedings of the National Academy of Sciences of the United States of America 102 (2005) 14215-14220. (Pubitemid 41429678)
116. C.T.T. Wong, D.K. Rowlands, C.-H. Wong, T.W.C. Lo, G.K.T. Nguyen, H.-Y. Li, J.P. Tam, Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment, Angewandte Chemie International Edition 51 (2012) 5620-5624.
117. T.L. Aboye, H. Ha, S. Majumder, F. Christ, Z. Debyser, A. Shekhtman, N. Neamati, J.A. Camarero, Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity, Journal of Medicinal Chemistry 55 (2012) 10729-10734.
118. J.A. Getz, O. Cheneval, D.J. Craik, P.S. Daugherty, Design of a cyclotide antagonist of neuropilin-1 and -2 that potently inhibits endothelial cell migration, ACS Chemical Biology 8 (2013) 1147-1154.
119. R. Eliasen, N.L. Daly, B.S. Wulff, T.L. Andresen, K.W. Conde-Frieboes, D.J. Craik, Design, synthesis, structural and functional characterization of novel melanocortin agonists based on the cyclotide kalata B1, Journal of Biological Chemistry 287 (2012) 40493-40501.
120. S. Gunasekera, F.M. Foley, R.J. Clark, L. Sando, L.J. Fabri, D.J. Craik, N.L. Daly, Engineering stabilized vascular endothelial growth factor-A antagonists: synthesis, structural characterization, and bioactivity of grafted analogues of cyclotides, Journal of Medicinal Chemistry 51 (2008) 7697-7704.
121. C.P. Sommerhoff, O. Avrutina, H.-U. Schmoldt, D. Gabrijelcic-Geiger, U. Diederichsen, H. Kolmar, Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase β, Journal of Molecular Biology 395 (2010) 167-175.
122. J.A. Getz, J.J. Rice, P.S. Daugherty, Protease-resistant peptide ligands from a knottin scaffold library, ACS Chemical Biology 6 (2011) 837-844.
123. R.H. Kimura, R. Teed, B.J. Hackel, M.A. Pysz, C.Z. Chuang, A. Sathirachinda, J.K. Willmann, S.S. Gambhir, Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer, Clinical Cancer Research 18 (2012) 839-849.
124. P. Thongyoo, N. Roque-Rosell, R.J. Leatherbarrow, E.W. Tate, Chemical and biomimetic total syntheses of natural and engineered MCoTI cyclotides, Organic and Biomolecular Chemistry 6 (2008) 1462-1470. (Pubitemid 351469865)
125. J.M. Stewart, Bradykinin antagonists: discovery and development, Peptides 25 (2004) 527-532. (Pubitemid 38591560)
126. A. Brust, E. Palant, D.E. Croker, B. Colless, R. Drinkwater, B. Patterson, C.I. Schroeder, D. Wilson, C.K. Nielsen, M.T. Smith, D. Alewood, P.F. Alewood, R.J. Lewis, χ-Conopeptide pharmacophore development: toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain, Journal of Medicinal Chemistry 52 (2009) 6991-7002.
127. A. Brust, C.-I.A. Wang, N.L. Daly, J. Kennerly, M. Sadeghi, M.J. Christie, R.J. Lewis, M. Mobli, P.F. Alewood, Vicinal disul fide constrained cyclic peptidomimetics: a turn mimetic scaffold targeting the norepinephrine transporter, Angewandte Chemie International Edition 52 (2013) 12020-12023.
128. C.S. Sevier, C.A. Kaiser, Formation and transfer of disulphide bonds in living cells, Nature Reviews. Molecular Cell Biology 3 (2002) 836-847. (Pubitemid 35285274)